Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Positive Initial Results for Novel COVID-19 Drug Molnupiravir First Tested at Sheba

Studies indicate a quicker decline in the infectious virus among individuals with early COVID-19 treated with Molnupiravir

According to U.S. drugmaker Merck & Co Inc., initial results of studies on the experimental antiviral drug Molnupiravir it is developing with Ridgeback Bio suggest a reduction in the required duration for a negative COVID-19 indication from nasopharyngeal swab tests applied to study participants with early symptomatic COVID-19.

Sheba Medical Center was the first hospital in the world to collaborate with Merck & Co, Inc. and conduct a clinical trial of Molnupiravir on COVID-19, which was originally designed to combat the flu. Molnupiravir works by causing mutations in the enzyme responsible for replicating the virus.

Presently, Molnupiravir is in Phase II/III clinical trials, set to be completed by May.
“We are very pleased to share our initial Phase II infectivity data. At a time where there is an unmet need for antiviral treatments against COVID-19, we are encouraged by these preliminary data,” said Dr. Wendy Painter, Chief Medical Officer of Ridgeback Bio.

Elisheva Fisher: Nurturing Hope and Strength at Sheba’s Safra Children’s Hospital
Elisheva navigates her responsibilities with a profound sense of purpose, creating an environment where medical care is interwoven with emotional support. Her presence is a…
Read More
An Inspirational Model for Pediatric Psychiatric Care in Israel and Beyond
In an era where mental health has earned critical attention, finding compassionate and effective treatment for pediatric psychiatric concerns has become an objective for many…
Read More
Daphna Hutt's Story
Saving Lives One Transplant at a Time – Daphna Hutt’s Story
“Being passionate and dedicated to what you're doing is the best thing you can do for your patients and their families. That's obvious to me.…
Read More